APA (7th ed.) Citation

Tiepolt, S., Becker, G., Wilke, S., Cecchin, D., Rullmann, M., Meyer, P. M., . . . Brust, P. (2021). (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine & Molecular Imaging, 48(3), 731. https://doi.org/10.1007/s00259-020-05029-w

Chicago Style (17th ed.) Citation

Tiepolt, Solveig, et al. "(+)-[18F]Flubatine as a Novel α4β2 Nicotinic Acetylcholine Receptor PET Ligand—results of the First-in-human Brain Imaging Application in Patients with β-amyloid PET-confirmed Alzheimer's Disease and Healthy Controls." European Journal of Nuclear Medicine & Molecular Imaging 48, no. 3 (2021): 731. https://doi.org/10.1007/s00259-020-05029-w.

MLA (9th ed.) Citation

Tiepolt, Solveig, et al. "(+)-[18F]Flubatine as a Novel α4β2 Nicotinic Acetylcholine Receptor PET Ligand—results of the First-in-human Brain Imaging Application in Patients with β-amyloid PET-confirmed Alzheimer's Disease and Healthy Controls." European Journal of Nuclear Medicine & Molecular Imaging, vol. 48, no. 3, 2021, p. 731, https://doi.org/10.1007/s00259-020-05029-w.